importance by inducing vasospasm at sites of impaired endothelial function and thrombus forma lion. 3. Adenosine is generated by enzymic degradation of ATP. Its formation is enhanced during ischaemia. Adenosine inhibits noradrenaline release from sympathetic nerve endings, causes vasodilatation via endothelium-dependent and endotheliumindependent actions, has important anti-arrhythmic properties and prevents deleterious sequelae of ischaemia. In humans, adenosine evokes a sympatho-excitatory reflex mediated by chemically sensitive receptors and afferent nerves in the kidney, heart and forearm. This reflex may he active during exercise and ischaemia and, because of its potential adverse consequences, it should be considered when developing new therapies to poten tiate the anti-ischaemic actions of endogenous adenosine in humans. Adenosine appears to mediate ischaemia-induced pain; a reduced sensi tivity to adenosine may underlie silent ischaemia. 4. New drugs that interact with adenosine forma tion or degradation or with adenosine receptors are under development. These have potential thera peutic application in the treatment of ischaemia and other circulatory disorders.
INTRODUCTION
The cardiovascular actions of extracellular nucleo sides and nucleotides have been recognized since the beginning of this century [1], but a comprehen sive understanding of their interstitial formation, degradation and mode of action and their (patho)physiological significance has only recently been accomplished [2] , They appear to be involved in modulation of central nervous system actions, immune function, thrombocyte aggregation and regulation of renal and gastrointestinal homoeostasis, and may influence virtually every body function through their interaction with the autonomic nervous system [3] , This review will focus on the extracellular actions of two purines: adeno sine and ATP, and in particular their role in the modulation of the cardiovascular system. Although purine receptors in the brain may contribute to ressurc refutation, we o *<»/* /vi beyond the scope of this review.
FORMATION, RELEASE AND DEGRADATION OF ADENOSINE AND ATP
Within the cell, culenositit' is primarily formed by two metabolic routes [4J. One is from ATP, by degradation, via ADP and AMP to adenosine. This pathway is accelerated when there is a mismatch between energy supply and demand and probably represents the main route of adenosine formation during ischaemia, The hydrolysis of AMP is catalysed by ^'-nucleotidase, which is present both in the intracellular (cytosolic form) as well as the extracellular space (membrane-bound form). In the second pathway, adenosine is formed by hydrolysis of ATP via A '-adenosylmethioninc to tV~adenosyl-homocysteine which in turn is hydrolysed to adeno sine. This reaction is catalysed by .V-adenosylhomoeysteine hydrolase. This route is oxygen insensitive and is probably of minor importance during ischaemic conditions. Adenosine diffuses through the cellular m em brane between the extracellular and intracellular space. This bidirectional process [5] is gradient dependent and is facilitated by a nucleoside transporter that is located in the plasma m em brane of many cells such as the endothelial cells, erythro cytes, cardiomyocytes and vascular smooth muscle I \ A part from a cellular source of adenosine, adeno sine formation may occur from extracellular ATP that can be degraded rapidly to adenosine by ectonucleotidases which are widespread and present on the extracellular surface of vascular smooth muscle cells and endothelium [6] . The endothelium appears to play a key role in uptake and metabolism of luminally applied adenosine [7] , but it is also a major source of endogenous adenine nucleosides and nucleotides. The endothelial release of adenine sosides and nucleotides is increased by /¿-adrenergic stimulation [6] , Noradrenaline-induced activation of 5'-nucleotidase may play a role in this interaction between endothelial adenosine form a tion and the sympathetic nervous system [8] .
ATP is released by exocytosis from aggregating thrombocytes and from sympathetic nerve endings where it is co-released with noradrenaline [3, 9] . In most cells, cytoplasmic ATP concentrations are high and simple diffusion of ATP through the cell m em brane may partly account for extracellular ATP.
During increased blood flow [10] , sympathetic nerve stimulation [ 11] , or application of well-known vasodilators like bradykinin and acetylcholine [12] , endothelial cells appear to release ATP. Cardiac isclniemia evokes an increase in plasma nucleotide concentration in the venous effluent which is under estimated by vascular eetonueleotidase activity [6 ] , During normal oxygenation, intracellular adeno sine and AM P concentrations are low. In this situa tion, extracellular adenosine will be transported rapidly to the intracellular com partm ent where it is further inactivated by phosphorylation to A M P or deamination to inosine. An extracellular form of adenosine deaminase exists. Intracellular deam ina tion after uptake is probably of greater importance in humans [13] ,
PURINERGIC RECEPTORS
Cardiovascular responses to purines are mediated by m em brane-bound receptors that are subdivided into Pi-and p 2-purinergic receptors (Table 1 ) [14] . This subdivision is based on the potency order of agonists (A T P > A D P > A M P > adenosine and adenosine > A M P > A D P > ATP for the IV and Pi-purinergic receptor respectively), the Pi-but not P2-purinergie receptor antagonistic properties of xanthine derivatives, and differences in intracellular second messengers [15] .
Pi-purinergic rcceptors were originally subdivided into Ai and A 2 , receptors. This differentiation has been verified by molecular techniques [16] , Both receptors are linked to G-proteins, A 1-receptor stimulation evokes a Gi-mediated decrease in adenylate cyclase activity with subsequent reduction in intracellular cAMP levels. Ai receptors are linked to other effector systems (phospholipasc C, potas sium and calcium channels [17, 18] ). Ai-receptorm ediated opening of KATP-channels [19] may play a role in the phenom enon of ischaemic precondi tioning (see below). The A 2 receptor is associated with a Gs binding protein and stimulation of this receptor increases adenylate cyclase activity with a subsequent increase in intracellular cAMP levels. Recently, the existence of a distinct A 3 adenosine receptor has been demonstrated [20] . This receptor is less sensitive to antagonism by methylxanthines and can be stimulated specifically by a synthetic adenosine derivative, N6-2-(4-aminophenyl)ethyIadenosine (A PNEA ). Like the other adenosine recep tors, the A 3 receptor is coupled to a G-protein.
Stimulation of the A3 receptor reduces the intra cellular cAM P concentration. In pithed rats, intra venous infusion of APNEA evokes a hypotensive response which is mediated by mast cell degranula tion [21] , In the rabbit heart this receptor has been implicated in ischaemic preconditioning (see below) [22] . Advances in molecular biology will probably reveal many other subclasses of the adenosine receptor whose specific pharm acological or physio logical effects, distinct from Ai-or A a-reccptor stimulation, will need to be elucidated. The vascular IVpurinorgic receptor has been subdivided into P2x-and P2y-purincrgic receptors based on rank-order differences in agonist potencies and different vascular effects (Table 1) [23] . The existence of a separate vascular 'pyrimidine* or 'nucleotide' receptor with affinity for both A TP and UTP has also been suggested [24, 25] . W hether this represents a distinct, so-called Fsu-purinergic receptor, or is a member of the VPay purinoceptor family' [26] depends on w hether U TP acts as its endogenous ligand [27] , Based on pharmacological evidence, a further subdivision of P^-and Pay-purinoceptors has been proposed [26, 28] .
A m ore definite characterization of cardiovascular Pa-receptors is hindered by the lack of selective, competitive receptor antagonists [27] . T he Pax-purincrgic receptor agonist, a,/i-methylene ATP, has been successfully applied to perform radioligand studies on P2 purinoreceptors and to desensitize P2x-pu.rinergic receptors [29, 30] . A lthough desensiti zation with a,//-methylene A TP may antagonize P2x-purinoceptor-mediated responses in vitro, repeated application of a,//-methylene A T P in vivo not only inhibits the vasoconstrictor effect of ATP, b u t may also attenuate the vasoconstrictor effect of noradrenaline, angiotensin II and vasopressin [31] . In addition, the ability of a,//-methylene ATP to inhibit A TP-induccd effects varies enormously [32] . Suram in has been reported to inhibit P2x purinoceptors. However, this drug also inhibits the Pay purinoceptor and several enzymes including possibly eetophosphatases [33, 34] , A classification of P2 purine receptors, based on potency differences between various A TP deriva tives, can be confounded by differences in degrada tion of ligands by eetophosphatases [35] .
A Pay-like receptor with seven transm em brane domains has been isolated from turkey and chicken brain but is not expressed in the heart [36, 37] , A P211 receptor has been cloned from hum an airway and colonic epithelium [38] , This receptor also contains seven m em brane-spanning dom ains, characteristic of G-protein-eoupled receptors, but is expressed in the heart. Two pharmacologically and structurally different Pax-purinergie receptors have been cloned from rat vas deferens and phaeoehromoeytoma PC 12 cells [39, 40] . As anticipated from voltage-dam p studies, both receptors are ligandgated ion channels. Thus, m olecular techniques confirm a heterogeneity of Pa purinoceptors as anticipated by pharmacological observations, A part from vascular Pa-purinergie receptors, specific Parpurinergie receptors have been dem on strated on thrombocytes [41] . A DP is the most potent endogenous agonist for this receptor and ATP is an endogenous antagonist stimulation results in throm bocyte activation and subsequent thrombus formation. A selective and possibly competitive antagonist of this receptor has been synthesized [43] , In the future, this may have clinical im portance as an anti-throm botic agent. Stim ulation by A T P 4" of a Pa* purinoceptor in non-excitable cell types such as leucocytes, parotid acinar cells and 3T6-transform ed fibroblasts induces non-sclective pores and may be involved in cell fusion [44, 45] . Finally, a Pad purinoceptor has been recognized with diadenosine polyphosphates (Ap/,A; n = 3 -6 ) as endogenous ligands. Ap<iA is stored in synaptic vesicles and chromaffin granules and may play a role as a co-transm itter in the nervous system [46] , This receptor (class?) has not been fully characterized. Som e of the described effects of diadenosine polyphosphates may be mediated by other P2 receptors [46, 47] . W hen more structural data, as obtained from molecular techniques, and truly selective antagonists become available, major changes in this classification of P2 purinoceptors will probably occur. As yet, no generally accepted classi fication system for Pa purinoceptors exists [27] ,
CARDIOVASCULAR EFFECTS OF PURINERGIC RECEPTOR STIMULATION

Vascular wall
ATP exerts two vascular actions that are opposite and m ediated by two distinct Pa-purinergic receptors located on endothelium and vascular smooth muscle cells ( Table 2) , The endothelial receptor evokes an endothelium -m ediated vasodilator response ( Fig. I ) [49] , O n vascular sm ooth muscle cells, Pax-purinergie receptor stim ulation results in a vasoconstrictor response [50] that has also been observed in human vessels in vitro [51] , but since the endothelium plays an im portant role in degradation and uptake of purines, only a m inor part of luminally applied ATP will probably reach the vascular smooth muscle cells [52] , Indeed, if endothelial function is intact, A TP as released during thrombocyte aggregation causes vasodilatation [53] . The receptor on vascular smooth muscle cells will preferentially be stimulated by uUerstitially released A TP as occurs from sympa thetic nerve endings ( Fig. 1) . Biochemical, histochemieal, eleetrophysiologieal and pharmacological evidence supports the hypothesis that ATP is released from sympathetic nerve endings, together with noradrenaline [3, 54] . In the mesenteric vascular bed of the rat, subthreshold doses of ATP potentiate the vasoconstrictor response to noradre naline but not to 5'-hydroxytryptamine or potassium chloride, indicating a specific facilitating synaptic interaction between ATP and noradrena line [55] . A direct, endothelium-independent* relaxing effect of ATP on vascular sm ooth muscle cells has also been observed, suggesting the presence o f P2v purinoceptors [56, 57] .
W hen infused into the brachial artery of healthy humans, A TP induces a dose-dependent vasodilator response, with high concentrations inducing maximal [48] A îi, A3 Pî;
P2 :
P2u Pat P2ï P2d May be involved in macrophage fusion
Release of EDRFs
Vasoconstriction vasodilatation, indicating that the vasodilator action of luminally applied ATP is not limited by stimula tion of P2x purinoceptors or the release of endothelium-derived contracting factors [58] . These responses to ATP could not be inhibited by theophylline and the vasodilator response to ATP was approximately 10 times more potent than the vasodilator response to equimolar doses of adeno sine, indicating that Pi purinoeeptor activation is not responsible for the vasodilator response to ATP [58] . Adenosine induces a vasodilator response via Aa-purinergic receptor activation in most vessels (see Fig. I ) [59] . Although the Ai-purinergic receptor may mediate vascular relaxation via opening of A T P-dependent potassium channels [18] , this receptor subtype is generally believed to be involved in a vasoconstrictor action of adenosine in glomerular afferent arterioles (see below) and possibly also in the pulmonary vascular bed [60] . In humans however, only a vasodilator response to adenosine in the pulmonary vascular bed has been described [61] .
An intact endothelium is not obligatory for the vasodilator action of adenosine [62] , but because some studies show a reduced vasodilator response to adenosine when the endothelium is removed, adeno sine receptors may be present on these cells [49] . Inhibition of nitric oxide synthase has been shown to inhibit adenosine-m ediated vasodilatation [63] , tly, As-adenosine receptors have been dem onstrated on human endothelial cells [64] , but there is some debate with regard to their functional significance. The site of adenosine application or formation may determine whether the vasodilator response is mediated by a direct effect on the vascular sm ooth muscle cells (interstitial adenosine) or w hether the endothelium is involved (luminal adenosine) [65] . In humans, infusion of adenosine into the brachial or coronary arteries results in vasodilatation [66, 67] . The latter serves as the basis for the adenosine stress test for inducible ischaemia in patients undergoing this test for the evaluation of coronary artery disease [68] . This vasodilatation can be antagonized by caffeine and theophylline, indicating a Pirpurinoceptor-mcdiated effect. Nitric oxide participates in this vasodilator response [69] , supporting a role for the endothelium in the vascular action of intraluminally applied adenosine in vivo.
Ai purinoceptors are also reported to mediate a vasodilator effect via opening of ATP-dependent potassium channels [18] . This potassium channel can also be activated by stimulation of A 2 purinoceptors [70] . W e have not been able to dem onstrate a role for A TP-dependent potassium channels in the forearm vasodilator response to adenosine in humans [69] .
A part from their direct influence on vascular tone, purines inhibit noradrenaline release from sympathetic nerve endings by presynaptic modula tion (see Fig. 1 ). Most studies on this subject point towards an adenosine-induced Ai-purinergic receptor-m ediated mechanism. ATP, via yet unclas-sided purinergic receptor subtypes (P:y and a possible Pj purinoceptor), may be involved as well [71, 72] . Using nucleoside transport inhibition to increase adenosine concentrations at sites of form a tion, we recently dem onstrated presynaptic m odula tion of noradrenaline release from sympathetic nerve endings in hum ans in vivo [73] .
Based on the experim ental data above, Burnstock and Sneddon [3] hypothesized that ATP is co-released with noradrenaline by sympathetic nerve endings, induces a vasoconstrictor response in concert with noradrenaline and is rapidly degraded to adenosine which presynaptieally inhibits sympa t i c neurotransm itter release thus providing a providing a negativc-fcedback loop. T h e activity of this feedback loop may be controlled by eetonucleotidase activity [74] .
Heart
In addition to causing coronary vasodilatation and presynaptic inhibition of noradrenaline release, purines have negative chronotropic, drom otropic and inotropic effects in isolated heart preparations, A TP is thought to induce its negative chronotropic and drom otropic effects after degradation to adeno sine [75] . However, under certain experimental conditions, atropine or vagotomy can attenuate these actions, indicating that this effect is at least partially vagally m ediated [76] . igative chronotropic actions. Adenosine depresses sino-atrial node activity and shifts the earliest site of atrial activation from the sino-atrial node towards the crista terminalis region. At high concentrations, adenosine may even cause sino-atrial exit block. Adenosine may also depress atrioventric ular and ventricular escape rhythms. In patients with a ventricular escape rhythm, heart rate is reduced in response to adenosine, especially when the escape rhythm is accelerated by isoproterenol. These effects are probably m ediated by Ai-adenosine receptor stimulation [77] , In the atrium, this receptor is id via a G -protcin to an acctylcholinedependent potassium channel. Activation of this channel results in hyperpolarization of pacemaker cells and subsequent reduction in the frequency of depolarizations [78] . In the intact organism, the adenosine-induced stimulation of reflex mechanisms may result in an increase in heart rate, which strongly contrasts with its effect on the sino-atrial node (see below).
Negative dromotropic actions. Adenosine prolongs atrioventricular conduction time in a dependent manner. Its site of action is probably the proximal portion of the atrioventricular junction. Based on the rank order of potency of different adenosine analogues and the use of specific antago nists, Ai-adenosine rceeptors are thought to be involved [79, 80] . The ability of adenosine to induce atrioventricular block has led to its widespread clinical use in the diagnosis and treatment of broad complex tachycardias [81, 82) . Bolus infusions are used for this purpose to prevent the reflexly induced sympathetic excitation that occurs when adenosine is infused more slowly [83] .
(Anli-)arrliythinic properties. Adenosine can atten uate ischaemia-and catecholamine-induced arrhyth mias in experimental preparations [84, 85] via Ai-adenosine receptors, probably by preventing catecholamine-induced calcium influx and subse quent afterdepolarizations [77] . ATP also inhibits isoproterenol-induced calcium influx, probably by stimulating Ai-adenosine receptors after its degrada tion to adenosine [77] , When ATP alone (i.e. without isoproterenol pretreatm ent) is applied to isolated myocardial cells, calcium influx is increased. This effect is thought to be related to Pa-purinergic receptor stimulation [86] and may contribute to ATP-induced automatieity. Alternatively, in isolated myocardial cells, ATP hydrolysis may activate the chloride/bicarbonate exchanger. The ¡ ? intracellular acidification may induce arrhythmic activity, providing a Pz-purinergic receptor-indepen dent mechanism [87] .
'wntive inaimmc actions. Adenosine has a negative Inotropic effect on both atrial and ventricular myocardium when contractility is increased with isoproterenol, probably by antago nizing the isoproterenol-induced increase in intra cellular eAMP [77] . In the atrium, adenosine also has a direct, i.e. without isoproterenol pretreatm ent, negative inotropic action, probably by increasing potassium efflux and subsequent hyperpolarization. These effects are mediated by Ai-adenosine receptor stimulation [77] . fn contrast to adenosine, ATP exerts a positive inotropic action on both atrial and ventricular myocardial cells [88] by increasing the intracellular calcium concentration.
Kidney
In contrast to most other vascular beds, adenosine induces Ai-reeeptor-m ediated vasoconstriction in the outer renal cortex that appears to be confined to the glomerular afferent arterioles. Simultaneously, adenosine dilates the efferent glomerular arterioles via Aa-adenosine receptor stimulation [89] , Acting in concert, these effects of adenosine lower glomerular filtration rate. The vasoconstrictor effect occurs immediately upon adenosine infusion, while the vasodilator response develops more slowly, opposing effects of adenosine may explain the biphasic response of renal blood flow but a constant ression of glomerular filtration rate during infusion of adenosine into the renal artery [89] , In the rat kidney, adenosine and angiotensin II act synergistically on afferent glomerular arterioles [90 Adenosine-induced release of endothelium-derived relaxing factor (ED RF) probably contributes to the efferent arteriolar vasodilatation [91] . Inhibition of tubuloglom erular feedback by selective adenosine receptor antagonists and adenosine deaminase, as well as its stimulation by adenosine deaminase inhibition and nucleoside transport inhibition, is im portant evidence in favour of adenosine as a m ediator of these phenomena [2] .
A denosine inhibits renal renin release via A i-adenosine receptor stimulation [92, 93] , resulting in reduced angiotensin II production and subse quent aldosterone release. Renal erythropoietin production is increased by Az-adenosine receptor stimulation [94] .
T he renal effects of ATP are less well assessed. In the rat, A TP induces a vasoconstrictor response that appears to be most pronounced in afferent (preglom erular) arterioles. The efferent arterioles are not affected by A TP [95] . ATP may also be involved in tubuloglom erular feedback [96] . Mesangial cells contain Pi y purinoceptors [97] , but their physiological role is, to our knowledge, not clear.
The direct tubular effects of purine receptors are beyond the scope of this review.
EFFECTS OF ADENOSINE ON AFFERENT NERVE ENDINGS
In conscious humans and some animals, adeno sine stimulates carotid and aortic chemoreceptors 83] and afferent nerves in the kidney [98] , heart [99, 100] and forearm muscle [101] . Stimulation of these afferent nerves activates the sympathetic nervous and respiratory systems [102, 103) , causing a subsequent increase in systolic blood pressure, plasma renin activity and ventilation [83, 104, 105] . The increase in heart rate is probably mediated by concom itant deactivation of the parasympathetic nervous system, since it can be antagonized by atropine but not by propranolol [106] , These excita tory effects of intravenous adenosine infusion are on an intact autonomic reflex arc [83] , which probably explains why these effects arc blunted in anaesthetized humans [107] . An increase in systolic blood pressure is not always observed during intravenous infusion of adenosine into healthy volunteers [108, 109] , probably due to differ ences in the degree of their caffeine abstinence. In the studies in which no increase in systolic blood pressure is observed, caffeine abstinence is invari ably brief or totally absent. A fter ingestion of two cups of regular coffee, plasma caffeine concentra tions are in the range of 4 -5 mg/1 [1.10], which is sufficiently high to antagonize the haemodynamic effects of intravenous adenosine infusion [104] , The plasma half-life time of caffeine after ingestion of two cups of coffee ranges from 2 to 8.5 h [110] . Therefore, a 24 h period of caffeine abstinence is important to prevent underestim ation of adenosineinduced haemodynamic and neurohum oral effects. An increase in systolic blood pressure, heart rate and plasma catecholamines has also been observed in resting man after administration of the adenosine transport inhibitor dipyridamole [111] . changes could be inhibited by previous administra tion of caffeine or theophylline [ 111, 112] , suggesting that adenosine is form ed under baseline conditions and has functionally im portant actions. These effects of endogenous adenosine have recently been replicated by the m ore selective nucleoside transport inhibitor draflazinc [113] . The excitatory effects of dipyridamole might explain its lack of benefit on cardiovascular mortality in large trials [11.4, 115] ,
In the heart and skeletal muscle, stimulation of adenosine-sensitive afferent nerves induces ischaemia-likc pain [116] . W hether anginal pain and sympathetic activation arc elicited by stimulation of the same afferent nerves is unknown. In healthy volunteers, sympatho-cxcitation is a m ore sensitive marker of adenosine-sensitive afferent nerve stimu lation than the induction of chest discomfort [113] . In patients with atherosclerotic heart disease, intra coronary infusion of adenosine can mimic both the nature and location of ischaemic pain [117] , suggesting that adenosine may be the chemical mediator of angina in this condition. Chest pain is not provoked when adenosine is infused into patients with total cardiac afferent denervation, i.e. orthotopic cardiac transplant recipients [118] . In contrast to subjects with intact cardiac innervation, systolic blood pressure falls in these transplant patients, suggesting that a significant contributor to the sympatho-cxcitation observed when adenosine is infused in normal subjects is a reflex response to stimulation of adenosine-sensitive cardiac afferent nerve endings [99, 1 19, 120] .
Patients with coronary artery disease manifest a spectrum of responses to ischaemia, from chest discomfort to a total lack of awareness. The syndrome of silent ischaemia, in which no chest pain is experienced, has attracted considerable attention, but the mechanism responsible for this variation in the expression of ischaemia between subjects, and within the same subject on different occasions, remains uncertain. The severity of chest pain in response to intravenous adenosine infusion is somewhat less in those with predominantly silent ischaemia than in subjects who experience angina [121J, but the role of endogenously formed adeno sine in this variable perception of ischaemia is as yet unexplored. As the extent of myocardium exposed to ischaemia may have a bearing on whether or not this stimulus is perceived as pain [122] , there may be a quantitative relationship betw een the am ount of adenosine generated and the development of angina. Alternatively, silent ischaemia may be caused by selective loss of adenosine-sensitive cardiac afferent nerves (certainly silent ischaemia is associated with autonom ic neuropathy in patients with diabetes mellitus [123] ), or by decreased responsiveness of receptors on these afferent nerve endings to adenosine. We are pursuing these latter hypotheses.
A part from sympathetic afferent nerves, the heart contains adenosine-sensitive vagal afferent nerves that are located in the inferoposterior wall of the left ventricle [124] . Stimulation of these afferent nerves may explain a recent observation that the effect of dipyridamole infusion on heart rate is related to the site of the perfusion defect on thallium scanning -with attenuation of the heart rate response in patients with inferoposterior, as opposed to anterior left ventricular hypoperfusion (A, Zahedi, J. S. Floras and R. J. Burns, unpub lished work).
ADENOSINE: A NATURAL DEFENCE AGAINST THE CONSEQUENCES OF ISCHAEMIA
Extracellular form ation of adenosine is increased during hypoxia and ischaemia [125] . Several effects of locally form ed adenosine are assumed to be beneficial in situations of reduced oxygen supply [126] , In the heart, its negative inotropic and chron otropic effects will reduce oxygen demand, and adenosine-induced vasodilatation will increase oxygen supply. Its clectrophysiologieal actions should reduce the risk of ischaemia-induecd arrhyth mias. Endogenous adenosine inhibits noradrenaline release and sympathetic neurotransmission during ischaemia [127, 128] . Presynaptic inhibition of noradrenaline release should attenuate catechola mine-induced arrhythmogenesis, vasoconstriction, thrombocyte aggregation and cytotoxicity [129] , In addition, adenosine inhibits thrombocyte aggrega tion [130] and may reduce the formation of leuco cyte-derived free radicals during ischaemia and reperfusion [131] . In several animal models, adeno sine has been shown to reduce myocardial infarct size, prevent ischaemia-induced cardiac arrhythmias and reduce myocardial stunning [132] [133] [134] , Adenosine appears to be involved in precondi tioning, defined as the increased tolerance of myocardium to a prolonged ischaemic insult, achieved by an initial brief exposure to ischaemia and reperfusion [ 135] . Preconditioning probably occurs in humans [136] . In animals, adenosineinduced preconditioning is m ediated by Ai receptors [137] , An A j-adenosine receptor may also be involved [22] . Protein kinase G appears to play a key role in the post-receptor mechanism of precondi tioning [138] , although interspecies differences exist in the im portance of protein kinase C in ischaemic preconditioning [139] . Activation of protein kinase C facilitates opening of A TP-dependent potassium channels, which are im portant in mediating ischaemic preconditioning [132, 140] . Alternative proteins that play a role in ischaemic precondi tioning and whose function could be modulated by protein kinase C activation are ecto-5'-nucleotidase and the nucleoside transporter [141] [142] [143] [144] , The role of nitric oxide in ischaemic preconditioning is not understood [144, 145] , Recently, ischaemic preconditioning has also been dem on strated in skeletal muscle of the pig [146] and in the brain [147] , indicating that rhythmic contractions are not obligatory for this phenom enon and suggesting that this protective mechanism against the sequelae of ischaemia might also be operative in patients with interm ittent claudication or with cerebral ischaemia. A denosine receptor stimulation and elevation of endogenous adenosine levels appear to reduce cerebral infarct size [148] and mediate cerebral ischaemic preconditioning [147] in animals. A deno sine attenuates the synaptic release of the cytotoxic amino acids glutam ate and aspartate by stimulation of presynaptic A i-adenosine receptors. Postsynaptically, adenosine depresses membrane calcium perm eability and increases potassium and chloride permeability, resulting in hyperpolarization and a reduced oxygen dem and [149] . Endogenous adeno sine prevents the occurrence of convulsions [150] , Dilation of cerebral arterioles will increase oxygen supply.
The role of the sympathetic nervous system in ischaemic preconditioning is controversial. In rabbits, pretreatm ent with reserpine prevents ischaemic preconditioning from reducing infarct size [151] . N oradrenaline is able to augment ischaemiainduced adenosine formation by activation of 5 '-nucleotidase [8] , Furtherm ore, noradrenaline adenosine) has been shown to induce ischaemic preconditioning [8] , In contrast, ischaemic preconditioning occurs in cultured human myocardial cells, a model that lacks sympathetic innervation [152] , In the isolated perfused rat heart, ischaemic preconditioning reduced noradrenaline release during sustained ischaemia ('neural precon ditioning') [153] , U nlike the beneficial effects of ischaemic preconditioning on infarct size, this reduc tion in noradrenaline release could not be attributed to endogenous adenosine release and could only partially be prevented by inhibitors of protein kinase C. These authors suggested a role for neural precon ditioning in m ediating the anti-arrhythmic effect of ischaemic preconditioning. D espite the increasing am ount of evidence that adenosine is beneficial in cardiac ischaemia, some conflicting results should also be mentioned. While in animals infusion of the adenosine receptor *\ r a antagonist 8-phcnyltheophylline in combination with deaminase exacerbates myocardial ischaemia during exercise [154] , in humans admini stration of theophylline, aminophylline or bamiphylline may reduce exercise-induced ischaemia as assessed by electrocardiographic param eters [155, 156] . Recently, this apparent discrepancy has been clarified.
Aminophylline has ai-adrenoceptor agonistic properties which redistribute myocardial flow during mild ischaemia in favour of the suben docardial myocardium [157, ischaemia in this area. However, during severe ischaemia, aminophylline exacerbates myocardial injury, probably by antagonizing the cardioprotective effects of endogenous adenosine [157] . In the rat heart, ischaemic preconditioning may not be mediated by «-adrenoceptors or adenosine receptors [159] . In the kidney, adenosine only marginally affects renal blood flow (due to a combination of afferent arteriolar constriction and efferent vasodila tation) but reduces tubular oxygen demand by atten uating glomerular filtration rate and tubular function [160] , Notwithstanding, the adenosine receptor antagonist theophylline prevented renal ischaemic damage in rabbits [161] . In human studies, theophylline attenuated nephrotoxicity from contrast media while the nucleoside transport inhibitor dipyridamole augm ented the contrast media-induced reduction in glomerular filtration rate [162] .
PHARMACOLOGICAL INTERVENTIONS
To date, pharmacological interventions are primarily directed towards adenosine-m ediated effects, Pi-and P2-purinergic receptor agonists and antagonists with varying degrees of selectivity have been described. For a detailed description, there are some excellent reviews on this topic [27] .
A part from compounds that directly interact with the adenosine receptor, some drugs with an indirect action have been developed. These can enhance adenosine release (AICA riboside [163] ) or reduce adenosine degradation by inhibiting cellular uptake of adenosine (e.g. nucleoside transport inhibitors such as nitrobenzylthioinosine, dipyridamole, dilazep and miofiazine derivatives like drafiazine [164] ) or inhibiting adenosine deaminase activity (deoxicoformycin). In addition, some compounds facilitate the binding of adenosine to its receptor through an allosteric mechanism. These allosteric enhancers may have the theoretical advantage of a possible adenosine receptor subtype specificity [165] . What these indirectly acting drugs have in common is that they affect adenosine-mediated actions only at sites of endogenous adenosine release, thereby preventing those systemic side-cffects that are assoc iated with intravenous infusion of adenosine or its analogues* For example, low-grade nucleoside trans port inhibition is able to potentiate the forearm vasodilator response to adenosine infusion into the brachial artery w ithout inducing unwanted sideeffects [113] .
CONCLUSIONS
The naturally occurring purines adenosine and ATP can induce a variety of effects that are m ediated by receptors located on the plasma m em brane. Studies in vitro and animal studies in vivo indicate that A TP is released from sympathetic nerve endings and aggregating thrombocytes, and cun inducc vasoconstriction via stimulation of Pax purinoceptors located on vascular smooth muscle cells and vasodilatation via receptors that are located on the endothelium and to a small extent also on smooth muscle cells. A denosine, the major pharmacologically active breakdown product of ATP, can induce vasodilatation via endotheliumdependent and endothelium -independent mechan isms. Furtherm ore, adenosine is able to reduce noradrenaline release from sympathetic nerve endings by a presynaptic mechanism. Adenosine can protect the heart against the sequelae of isehaemia and can induce ischaemic preconditioning. Many of these effects have now also been observed in humans in vivo. Exploitation of the cardioprotective effects of endogenous adenosine is a major challenge for cardiovascular pharmacology, In this respect, specific low-grade nucleoside transport inhibition is veiy promising.
Im portant progress has been m ade in the molec ular characterization of P2 purinoceptors. New insights into the structure of these receptors should facilitate the developm ent of specific P> purinoceptor antagonists and agonists that could further characterize the physiological im portance of purines ia the regulation o f various body functions and direct the design of pharm acological interventions of clinical benefit.
